Celyad Archives

News and Trends 6 Nov 2015

Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on the CAR-T field?

About 30%. That’s how Cellectis‘ NASDAQ stock price has jumped between the 4th and the 5th of November. But why? Basically, because of the first human success of their allogeneic CAR-T therapy! The Great Ormond Street Hospital (UK) treated a young patient with refractory relapsed Acute Lymphoblastic Leukemia (ALL) with Cellectis’ allogeneic UCART19 product candidate in June. To […]

November 6, 2015 - 2 minutesmins - By Jerome Topsent

News and Trends 29 Oct 2015

ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells

ERRATUM: I published a first article on Celyad’s new patent on last Tuesday where I made an error of judgement. Celyad’s US patent covers allogeneic CAR-T modified to reduce immunogenicity. In my previous article, I wrote that Celyad stated having obtained the first US patent on CAR-T, which is wrong. Last Tuesday, Celyad announced having […]

October 29, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 15 Sep 2015

Louvain-la-Neuve: A Belgian temple for success in cell therapy

Artificial three-dimensional tissues to regenerate bones and soft tissues: Novadip Biosciences’ dream is a step closer to reality after successfully closing a €28M Series A round. The spin-off of Université Catholique de Louvain coexists with Celyad and Promethera in a biotech cluster where cell therapy is the key protagonist. The financing round, led by New […]

September 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 28 May 2015

Biotechs outperformed in the top 40 European Tech Companies

EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs (Small and Medium-size companies), announced the launch of Tech 40, a label recognizing innovative European SMEs. Tech 40 puts young tech companies listed on Euronext markets – in Amsterdam, Brussels, Lisbon or Paris – under the spotlight. Companies awarded with the Tech 40 are operating in […]

May 28, 2015 - 2 minutesmins - By Nicolas Sainte-Foie

News and Trends 1 Apr 2015

Cardio3 will launch an IPO in the United States

Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced its intention to conduct a registered public offering in the United States. The timing, number of shares and price of the proposed offering have not yet been determined. A draft registration statement relating to […]

April 1, 2015 - 1 minutemin - By Lourdes Riquelme

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us